PR Newswire
20.02.2025
As reported by PR Newswire, Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine, a clinical stage generative artificial integlligence-driven biotechnology company, announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.
EurekAlert
03.03.2025
As reported by EureAlert, Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a commercial-stage biopharmaceutical company developing and commercializing innovative treatments for nervous system disorders, today announced a strategic research collaboration. Focused on certain potential targets, Insilico and Tenacia will collaborate during the early discovery stage of novel Central Nervous System (CNS) disease therapies, developing small molecule inhibitors from scratch to preclinical candidate nomination.
Source: Insilico Medicine and Tenacia Biotechnology a | EurekAlert!
PR Newswire
13.03.2025
As reported by PR Newswire, Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group (HKG:0806), one of Asia's largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission. Certain information contained in this website is compiled from third party sources. Whilst we have, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. We accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.
Apr 02, 2025
